Literature DB >> 15039212

Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer.

Regine Schneider-Stock1, Christian Mawrin, Christiane Motsch, Carsten Boltze, Brigitte Peters, Roland Hartig, Peter Buhtz, Anja Giers, Astrid Rohrbeck, Bernd Freigang, Albert Roessner.   

Abstract

The allele constitution at codon 72 of the p53 gene (CGC-arginine or CCC-proline) plays a major role in inducing apoptosis in p53 mutant cells. To verify this, we determined GC-status, p53-mutations, and p53-loss of heterozygosity (LOH) in a group of 54 squamous cell carcinomas of the head and neck (SCCHN). A novel approach, using a one-step real-time PCR analysis with fluorescent hybridization probes, was applied to detect the GC status in tumors and corresponding blood samples. p53 mutations in exons 4 to 8 were detected by PCR-SSCP-sequencing analysis. Apoptosis was determined immunohistochemically using antibodies against Fas, FasL, p53, Bcl2, and terminal deoxy-transferase-mediated dUTP nick end labeling (TUNEL) staining. The overall frequency of p53-LOH in SCCHN was 45.2%. In cases of LOH, there was a preferential loss of the proline allele, which was associated with an up-regulation of Bcl2 and lack of co-expression of Fas/FasL and, thus, impaired apoptosis (P < 0.001). Apoptosis was not observed in tumors carrying the arginine allele. p53 mutations were detected in 29.6% of SCCHN and preferentially occurred at the arginine allele (P = 0.01). p53 alterations were more frequently observed in tumors of the oral cavity, oropharynx and hypopharynx, whereas they were rare in larynx carcinomas (P = 0.07). The p53-LOH status was not found to be significantly correlated with sex, age, TNM-status, or tumor grading. We conclude that apoptosis is correlated with the allelic status of codon 72 in SCCHN. Homozygous proline 72 appears to be an important regulator of apoptosis via the Fas/FasL pathway in SCCHN.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039212      PMCID: PMC1615339          DOI: 10.1016/S0002-9440(10)63211-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors:  M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity.

Authors:  S Hanabuchi; M Koyanagi; A Kawasaki; N Shinohara; A Matsuzawa; Y Nishimura; Y Kobayashi; S Yonehara; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

Review 3.  Death receptors: signaling and modulation.

Authors:  A Ashkenazi; V M Dixit
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

4.  The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.

Authors:  M W Bennett; J O'Connell; G C O'Sullivan; C Brady; D Roche; J K Collins; F Shanahan
Journal:  J Immunol       Date:  1998-06-01       Impact factor: 5.422

5.  Genetic polymorphism and cancer susceptibility: fourteenth Sapporo Cancer Seminar.

Authors:  F J Gonzalez
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

6.  p53 mutations in head and neck cancer: new data and evaluation of mutational spectra.

Authors:  A F Olshan; M C Weissler; H Pei; K Conway
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-07       Impact factor: 4.254

Review 7.  The p53 network in head and neck cancer.

Authors:  Milena Gasco; Tim Crook
Journal:  Oral Oncol       Date:  2003-04       Impact factor: 5.337

8.  Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus.

Authors:  T J Liu; W W Zhang; D L Taylor; J A Roth; H Goepfert; G L Clayman
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

9.  Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype.

Authors:  C J van der Woude; P L M Jansen; A T G M Tiebosch; A Beuving; M Homan; J H Kleibeuker; H Moshage
Journal:  Hum Pathol       Date:  2002-07       Impact factor: 3.466

10.  p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.

Authors:  M Müller; S Wilder; D Bannasch; D Israeli; K Lehlbach; M Li-Weber; S L Friedman; P R Galle; W Stremmel; M Oren; P H Krammer
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  23 in total

1.  CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.

Authors:  Pedro A Andrade Filho; Daisuke Ito; Albert B Deleo; Robert L Ferris
Journal:  Cancer Immunol Immunother       Date:  2010-06-25       Impact factor: 6.968

2.  Relationship between the Arg72Pro polymorphism of p53 and outcome for patients with traumatic brain injury.

Authors:  Pascual Martínez-Lucas; Jerónimo Moreno-Cuesta; Dolores C García-Olmo; Francisco Sánchez-Sánchez; Julio Escribano-Martínez; Ana Cuartero del Pozo; Máxima Lizán-García; Damián García-Olmo
Journal:  Intensive Care Med       Date:  2005-07-09       Impact factor: 17.440

3.  TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.

Authors:  Ana Coelho; Augusto Nogueira; Sílvia Soares; Joana Assis; Deolinda Pereira; Isabel Bravo; Raquel Catarino; Rui Medeiros
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

4.  TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development.

Authors:  Natalia Volodko; Mohamed Salla; Bertus Eksteen; Richard N Fedorak; Hien Q Huynh; Shairaz Baksh
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

5.  Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri.

Authors:  Stefan Braeuninger; Regine Schneider-Stock; Elmar Kirches; James M Powers; David N Korones; Christian Mawrin
Journal:  J Neurooncol       Date:  2006-09-06       Impact factor: 4.130

6.  Fuzzy clustering demonstrates that codon 72 SNP rs1042522 of TP53 gene associated with HNSCC but not with prognoses.

Authors:  Ugo Borges Pinheiro; Carlos Alberto de Carvalho Fraga; Danilo Cangussu Mendes; Lucyana Conceição Farias; Cláudio Marcelo Cardoso; Christine Mendes Silveira; Marcos Flávio Silveira Vasconcelos D'Angelo; Kimberly Marie Jones; Sérgio Henrique Souza Santos; Alfredo Maurício Batista de Paula; André Luiz Sena Guimarães
Journal:  Tumour Biol       Date:  2015-06-23

7.  Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population.

Authors:  S Mitra; S Banerjee; C Misra; R K Singh; A Roy; A Sengupta; C K Panda; S Roychoudhury
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

8.  Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.

Authors:  Zhong-Zheng Zhu; Bing Liu; Ai-Zhong Wang; Hang-Ruo Jia; Xia-Xiang Jin; Xiang-Lei He; Li-Fang Hou; Guan-Shan Zhu
Journal:  J Zhejiang Univ Sci B       Date:  2008-11       Impact factor: 3.066

9.  Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.

Authors:  Marjanka K Schmidt; Johanna Tommiska; Annegien Broeks; Flora E van Leeuwen; Laura J Van't Veer; Paul D P Pharoah; Douglas F Easton; Mitul Shah; Manjeet Humphreys; Thilo Dörk; Scarlett A Reincke; Rainer Fagerholm; Carl Blomqvist; Heli Nevanlinna
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466

10.  MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.

Authors:  Nathan A Ellis; Dezheng Huo; Ozlem Yildiz; Lisa J Worrillow; Mekhala Banerjee; Michelle M Le Beau; Richard A Larson; James M Allan; Kenan Onel
Journal:  Blood       Date:  2008-04-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.